Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel
Executive Summary
Dynavax has already received two complete response letters for its hepatitis B vaccine; more patients who received Heplisav died or experienced cardiovascular events compared with the competitor arm.